Modification of the Rb-binding domain of replication-competent adenoviral vector enhances cytotoxicity against human esophageal cancers via NF-κB activity

Human Gene Therapy

Volumn 18, Issue 5, 2007, Pages 389-400

  Yamada, Katsumi ^a   Moriyama, Hiroaki ^a   Yasuda, Hisafumi ^a   Hara, Kenta ^a   Maniwa, Yoshimasa ^a   Hamada, Hirofumi ^b   Yokono, Koichi ^a   Nagata, Masao ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AXDADB 3; AXE1ADB; DNA; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOLYTIC ADENOVIRUS; PLASMID DNA; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; ESOPHAGUS CANCER; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN DOMAIN; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ADENOVIRUSES, HUMAN; AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; ESOPHAGEAL NEOPLASMS; GENE THERAPY; GENETIC VECTORS; HUMANS; NF-KAPPA B; PROTEIN BINDING; RECEPTORS, VIRUS; RETINOBLASTOMA PROTEIN; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 34249774020     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.126     Document Type: Article

References (48)

1. ADAMS, P.D., and KAELIN, W.G.J. (1995). Transcriptional control by E2F. Semin. Cancer Biol. 6, 99-108.
2. BARKER, D.D., and BERK, A.J. (1987). Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121.
3. BERNARDS, R., DE LEEUW, M.G.W., HOUWELING, A., and VAN DER EB, A.J. (1986). Role of the adenovirus early region 1B tumor antigens in transformation and lytic infection. Virology 150, 126-139.
4. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON JOHANNES, A., FATTAEY, A., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
5. BRAITHWAITE, A.W., CHEETHAM, B.F., LI, P., PARISH, C.R., WALDRON-STEVENS, L.K., and BELLET, A.J.D. (1985). Adenovirus-induced alterations of the cell growth cycle: A requirement for E1A but not E1B. J. Virol. 45, 192-199.
6. BREIDING, D.E., EDBAUER, C.A., YONG, J.T., BYRD, P., GRAND, R.J.A., GALLIMORE, P.H., and WILLIAMS, J. (1988). Isolation and characterization of adenovirus type 12 E1 host-range mutants defective for growth in nontransformed human cells. Virology 164, 390-402.
7. COOK, J.L., WALKER, T.A., WORTHEN, G.S., and RADKE, J.R. (2002). Role of the E1A Rb-binding domain in repression of the NF-κB-dependent defense against tumor necrosis factor-α. Proc. Natl. Acad. Sci. U.S.A. 99, 9966-9917.
8. FAHA, B., EWEN, M.E., TSAI, L.-H., LIVINGSTON, D.M., and HARLOW, E. (1992). Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science 255, 87-90.
9. FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P.S., MCDONNELL, T.J., MITLIANGA, P., SHI, Y.X., LEVIN, V.A., YUNG, W.K., and KYRITSIS, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 6, 2-12.
10. FUKUDA, K., ABEI, M., UGAI, H., SEO, E., WAKAYAMA, M., MURATA, T., TODOROKI, T., TANAKA, N., HAMADA, H., and YOKOYAMA, K.K. (2003). E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 63, 4434-4440.
11. GALLIMORE, P.H., BYRD, P.J., WHITTAKER, J.L., and GRAND, R.J.A. (1985). Properties of rat cells transformed by DNA plasmids containing adenovirus 12 E1 DNA or specific fragments of the E1 region: Comparison of transforming frequencies. Cancer Res. 45, 2670-2680.
12. GOMEZ-MANZANO, C., BALAGUE, C., ALEMANY, R., LEMOINE, M.G., MITLIANGA, P., JIANG, H., KHAN, A., ALONSO, M., LANG, F.F., CONRAD, C.A., LIU, T.J., BEKELE, B.N., YUNG, W.K., and FUEYO, J. (2004). A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 11, 1821-1828
13. GRANA, X., GARRIGA, J., and MAYOL, X. (1998). Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17, 3365-3383.
14. GRAND, R.J.A., IBRAHIM, A.P., TAYLOR, A.M.R., MILNER, A.E., GREGORY, C.D., GALLIMORE, P.H., and TURNELL, A.S. (1998). Human cells arrest in S phase in response to adenovirus 12 E1A. Virology 244, 330-342.
15. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B., and HARRIS, C.C. (1991). p53 mutations in human cancers. Science 253, 49-53.
16. HOUWELING, A., VAN DEN ELSEN, P.J., and VAN DER EB, A.J. (1980). Partial transformation of primary rat cells by the leftmost 4.5% fragment of adenovirus 5 DNA. Virology 105, 537-550.
17. HUBBERSTEY, A.V., PAVLIV, M., and PARKS, R.J. (2002). Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Ther. 9, 321-329.
18. JAKUBCZAK, J.L., RYAN, P., GORZIGLIA, M., CLARKE, L., HAWKINS, L.K., HAY, C., HUANG, Y., KALOSS, M., MARINOV, A., PHIPPS, S., PINKSTAFF, A., SHIRLEY, P., SKRIPCHENKO, Y., STEWART, D., FORRY-SCHAUDIES, S., and HALLENBECK, P.L. (2003). An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors. Cancer Res. 63, 1490-1499.
19. KAELIN, W.G.J. (1999). Functions of the retinoblastoma protein. Bioessays 21, 950-958.
20. KARIN, M., and LIN, A. (2002). NF-κB at the crossroads of life and death. Nat. Immunol. 3, 221-227.
21. KARIN, M., CAO, Y., GRETEN, F.R., and LI, Z.W. (2002). NF-κB in cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 2, 301-310.
22. KUCHARCZAK, J., SIMMONS, M.J., FAN, Y., and GELINAS, C. (2003). To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22, 8961-8982.
23. LAND, H., PARADA, L.F., and WEINBERG, R.A. (1983). Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596-602.
24. LASSAM, N.J., BAYLEY, S.T., and GRAHAM, F.L. (1979). Tumor antigens of human Ad 5 in transformed cells and in cells infected with transformation defective host range mutants. Cell 18, 781-791.
25. LEVINE, A.J., MOMAND, J., and FINLAY, C.A. (1991). The p53 tumour suppressor gene. Nature 351, 453-456.
26. LI, Y., GRAHAM, C. LACY, S., DUNCAN, A.M.V., and WHYTE, P. (1993). The adenovirus E1A-associated 130kDa-protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev. 7, 2366-2377.
27. MIYAKE, S., MAKIMURA, M., KANEGAE, Y., HARADA, S., SATO, Y., TAKAMORI, K., TOKUDA, C., and SAITO, I. (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. U.S.A. 93, 1320-1324.
28. MONTELL, C. FISHER, E.F., CARUTHERS, M.H., and BERK, A. (1982). Resolving the functions of overlapping viral genes by site-specific mutagenesis at a mRNA splice site. Nature 295, 380-384.
29. NAKAMURA, Y., WAKIMOTO, H., ABE, J., KANEGAE, Y., SAITO, I., AOYAGI, M., HIRAKAWA, K., and HAMADA, H. (1994). Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res. 54, 5757-5760.
30. NEMUNAITIS, J., and O'BRIEN, J. (2002). Head and neck cancer: gene therapy approaches. II. Genes delivered. Expert Opin. Biol. Ther. 2, 311-324.
31. NEMUNAITIS, J., GANLY, I., KHURI, F., ARSENEAU, J., KUHN, J., McCARTY, T., LANDERS, S., MAPLES, P., ROMEL, L., RANDLEV, B., REID, T., KAYE, S., and KIRN, D. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 15, 6359-6366.
32. QUINLAN, M.P., and GRODZICKER, T. (1987). Adenovirus E1A 12S protein induces DNA synthesis and proliferation in primary epithelial cells in both the presence and absence of serum. J. Virol. 61, 673-682.
33. RAYET, B., and GELINAS, C. (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947.
34. ROSS, S.R., LEVINE, A.J., GALOS, R.S., WILLIAMS, J., and SHENK, T. (1980). Early viral proteins in HeLa cells infected with adenovirus type 5 host range mutants. Virology 103, 475-492.
35. SATO, K., KASONO, K., OHBA, Y., YASHIRO, T., FUJII, Y., YOSHIDA, M.A., TSUSHIMA, T., and SHIZUME, K. (1987). Establishment of a parathyroid hormone-like factor-producing esophageal carcinoma cell line (EC-GI). Jpn. J. Cancer Res. 10, 1044-1048.
36. SAUTHOFF, H., PIPIYA, T., HEITHER, S., CHEN, S., BLECK, B., REIBMAN, J., CHANG, W., NORMAN, R.G., and ROM, W.N. (2004). Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol. Ther. 10, 749-757.
37. SHERR, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677.
38. SHIMADA, H., SHIMIZU, T., OCHIAI, T., LIU, T.L., SASHIYAMA, H., NAKAMURA, A., MATSUBARA, H., GUNJI, Y., KOBAYASHI, S., TAGAWA, M., SAKIYAMA, S., and HIWASA, T. (2001). Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg. Today 31, 597-604.
39. SHINOURA, N., YOSHIDA, Y., TSUNODA, R., OHASHI, M., ZHANG, W., ASAI, A., KIRINO, T., and HAMADA, H. (1999). Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of glioma. Cancer Res. 59, 3411-3416.
40. r gene product is required for viral DNA synthesis and for initiation of cell transformation. J. Virol. 57, 792-801.
41. STRAUSS, M., LUKAS, J., and BARTEK, J. (1995). Unrestricted cell cycling and cancer. Nat. Med. 1, 1245-1246.
42. TAKAHASHI, K., KANAZAWA, H., CHAN, C.-T., HOSONO, T., TAKAHARA, M., and SATO, K. (1990). A case of esophageal carcinoma metastatic to mandible and characterization of two cell lines (T.T and T.Tn) established from the oral tumor. Jpn. J. Oral Maxillofac. Surg. 36, 67-76.
43. TRIMARCHI, J.M., and LEES, J.A. (2002). Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell. Biol. 3, 11-20.
44. VAN DER EB, A.J., MULDER, C. GRAHAM, F.L., and HOUWELING, A. (1977). Transformation with specific fragments of adenovirus DNAs. I. Isolation of specific fragments with transforming activity of adenovirus 2 and 5 DNA. Gene 2, 115-132.
45. WHITE, E. (1995). Regulation of p53-dependent apoptosis by E1A and E1B. Curr. Top. Microbiol. Immunol. 199, 34-38.
46. WHYTE, P., BUCHKOVICH, K.J., HOROWITZ, J.M., FRIEND, S.H., RAYBUCK, M., WEINBERG, R.A., and HARLOW, E. (1988). Association between oncogene and anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334, 124-129.
47. WILLIAMS, J., WILLIAMS, M., LIU, C., and TELLING, G. (1995). Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Curr. Top. Microbiol. Immunol. 199, 149-175.
48. YOO, G.H., HUNG, M.C., LOPEZ-BERESTEIN, G., LAFOLLETTE, S., ENSLEY, J.F., CAREY, M., BATSON, E., REYNOLDS, T.C., and MURRAY, J.L. (2001). Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res. 7, 1237-1245.